Teva Pharmaceutical Industries revenue and financials
$39.13Change from previous close: −1.34%Absolute change: −$0.53
In the fiscal year ended December 2025, Teva Pharmaceutical Industries reported revenue of $17.26B (+4.32% year over year). Net income was $1.41B, a net margin of 8.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- 8.2%
- 2024: -9.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 39,857 | 40,040 | 40,748 | 39,856 | 40,131 | — |
| Current assets | 13,760 | 13,710 | 13,946 | 12,736 | 12,620 | — |
| Cash and equivalents | 3,655 | 3,741 | 3,556 | 2,203 | 2,161 | — |
| Receivables | 3,493 | 3,393 | 3,709 | 3,810 | 3,564 | — |
| Inventory | 3,221 | 3,176 | 3,179 | 3,323 | 3,497 | — |
| Net property, plant and equipment | 4,261 | 4,333 | 4,425 | 5,162 | 5,168 | — |
| Goodwill | 15,839 | 15,822 | 16,000 | 15,945 | 15,949 | — |
| Other intangible assets | 3,447 | 3,609 | 3,781 | 3,936 | 4,142 | — |
| Current liabilities | 15,646 | 13,532 | 13,456 | 11,491 | 11,861 | — |
| Accounts payable | 2,721 | 2,596 | 2,531 | 2,355 | 2,498 | — |
| Long-term debt | 12,092 | 14,015 | 14,986 | 16,766 | 16,763 | — |
| Total debt | 16,874 | 16,907 | 17,094 | 17,073 | 17,523 | — |
| Total liabilities | 32,100 | 31,808 | 32,834 | 32,602 | 33,297 | — |
| Total equity (incl. minority) | 7,757 | 8,232 | 7,914 | 7,254 | 6,834 | — |
| Retained earnings | -13,969 | -13,394 | -13,762 | -14,243 | -14,676 | — |
| Minority interest | 4.0 | 4.0 | 4.0 | 4.0 | 7.0 | — |